Alternative splicing of BCL‑X and implications for treating hematological malignancies (Review)
- Authors:
- Wanling Chen
- Jinggang Li
-
Affiliations: Department of Clinical Medicine, Xiamen Medical College, Xiamen, Fujian 361023, P.R. China, Department of Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian 350001, P.R. China - Published online on: July 18, 2021 https://doi.org/10.3892/ol.2021.12931
- Article Number: 670
-
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Boise LH, González-García M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nuñez G and Thompson CB: Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell. 74:597–608. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Opferman JT: Attacking cancer's Achilles heel: Antagonism of anti-apoptotic BCL-2 family members. FEBS J. 283:2661–275. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Delbridge AR and Strasser A: The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ. 22:1071–1080. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yang E and Korsmeyer SJ: Molecular thanatopsis: A discourse on the BCL2 family and cell death. Blood. 88:386–401. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Motoyama N, Kimura T, Takahashi T, Watanabe T and Nakano T: Bcl-x prevents apoptotic cell death of both primitive and definitive erythrocytes at the end of maturation. J Exp Med. 189:1691–1698. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Motoyama N, Wang F, Roth KA, Sawa H, Nakayama K, Nakayama K, Negishi I, Senju S, Zhang Q, Fujii S, et al: Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science. 267:1506–1510. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Shearn AI, Deswaerte V, Gautier EL, Saint-Charles F, Pirault J, Bouchareychas L, Rucker EB III, Beliard S, Chapman J, Jessup W, et al: Bcl-x inactivation in macrophages accelerates progression of advanced atherosclerotic lesions in Apoe(−/-) mice. Arterioscler Thromb Vasc Biol. 32:1142–1149. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wagner KU, Claudio E, Rucker EB, Riedlinger G, Broussard C, Schwartzberg PL, Siebenlist U and Hennighausen L: Conditional deletion of the Bcl-x gene from erythroid cells results in hemolytic anemia and profound splenomegaly. Development. 127:4949–4958. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Silva M, Richard C, Benito A, Sanz C, Olalla I and Fernández-Luna JL: Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N Engl J Med. 338:564–571. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Johnson JM, Castle J, Garrett-Engele P, Kan Z, Loerch PM, Armour CD, Santos R, Schadt EE, Stoughton R and Shoemaker DD: Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science. 302:2141–2144. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Rosa R, Villegas-Ruíz V, Caballero-Palacios MC, Pérez-López EI, Murata C, Zapata-Tarres M, Cárdenas-Cardos R, Paredes-Aguilera R, Rivera-Luna R and Juárez-Méndez S: Expression of ZNF695 transcript variants in childhood B-cell acute lymphoblastic leukemia. Genes (Basel). 10:7162019. View Article : Google Scholar : PubMed/NCBI | |
|
Handschuh L, Wojciechowski P, Kazmierczak M, Marcinkowska-Swojak M, Luczak M, Lewandowski K, Komarnicki M, Blazewicz J, Figlerowicz M and Kozlowski P: NPM1 alternative transcripts are upregulated in acute myeloid and lymphoblastic leukemia and their expression level affects patient outcome. J Transl Med. 16:2322018. View Article : Google Scholar : PubMed/NCBI | |
|
Zeilstra J, Joosten SP, van Andel H, Tolg C, Berns A, Snoek M, van de Wetering M, Spaargaren M, Clevers H and Pals ST: Stem cell CD44v isoforms promote intestinal cancer formation in Apc(min) mice downstream of Wnt signaling. Oncogene. 33:665–670. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Corujo D and Buschbeck M: Post-translational modifications of H2A histone variants and their role in cancer. Cancers (Basel). 10:592018. View Article : Google Scholar : PubMed/NCBI | |
|
Lee Y, Hong M, Kim JW, Hong YM, Choe YK, Chang SY, Lee KS and Choe IS: Isolation of cDNA clones encoding human histone macroH2A1 subtypes. Biochim Biophys Acta. 1399:73–77. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Harder JM, Ding Q, Fernandes KA, Cherry JD, Gan L and Libby RT: BCL2L1 (BCL-X) promotes survival of adult and developing retinal ganglion cells. Mol Cell Neurosci. 51:53–59. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
International Stem Cell Initiative, ; Amps K, Andrews PW, Anyfantis G, Armstrong L, Avery S, Baharvand H, Baker J, Baker D, Munoz MB, et al: Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol. 29:1132–1144. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI, Adams JM and Huang DC: Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 19:1294–1305. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Kluck RM, Bossy-Wetzel E, Green DR and Newmeyer DD: The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis. Science. 275:1132–1136. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Kim CN, Wang X, Huang Y, Ibrado AM, Liu L, Fang G and Bhalla K: Overexpression of Bcl-X(L) inhibits Ara-C-induced mitochondrial loss of cytochrome c and other perturbations that activate the molecular cascade of apoptosis. Cancer Res. 57:3115–3120. 1997.PubMed/NCBI | |
|
Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP and Wang X: Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked. Science. 275:1129–1132. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Gottschalk AR, Boise LH, Thompson CB and Quintáns J: Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2. Proc Natl Acad Sci USA. 91:7350–7354. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Minn AJ, Rudin CM, Boise LH and Thompson CB: Expression of bcl-xL can confer a multidrug resistance phenotype. Blood. 86:1903–1910. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Kamesaki S, Kamesaki H, Jorgensen TJ, Tanizawa A, Pommier Y and Cossman J: Bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res. 53:4251–4256. 1993.PubMed/NCBI | |
|
Walton MI, Whysong D, O'Connor PM, Hockenbery D, Korsmeyer SJ and Kohn KW: Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res. 53:1853–1861. 1993.PubMed/NCBI | |
|
Josefsson EC, James C, Henley KJ, Debrincat MA, Rogers KL, Dowling MR, White MJ, Kruse EA, Lane RM, Ellis S, et al: Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. J Exp Med. 208:2017–2031. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kaluzhny Y, Yu G, Sun S, Toselli PA, Nieswandt B, Jackson CW and Ravid K: Bcl-xL overexpression in megakaryocytes leads to impaired platelet fragmentation. Blood. 100:1670–1678. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Delbridge AR, Aubrey BJ, Hyland C, Bernardini JP, Di Rago L, Garnier JM, Lessene G, Strasser A, Alexander WS and Grabow S: The BH3-only proteins BIM and PUMA are not critical for the reticulocyte apoptosis caused by loss of the pro-survival protein BCL-XL. Cell Death Dis. 8:e29142017. View Article : Google Scholar : PubMed/NCBI | |
|
Afreen S, Bohler S, Müller A, Demmerath EM, Weiss JM, Jutzi JS, Schachtrup K, Kunze M and Erlacher M: BCL-XL expression is essential for human erythropoiesis and engraftment of hematopoietic stem cells. Cell Death Dis. 11:82020. View Article : Google Scholar : PubMed/NCBI | |
|
Hafid-Medheb K, Augery-Bourget Y, Minatchy MN, Hanania N and Robert-Lézénès J: Bcl-XL is required for heme synthesis during the chemical induction of erythroid differentiation of murine erythroleukemia cells independently of its antiapoptotic function. Blood. 101:2575–2583. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S, Kelly PN, Ekert PG, Metcalf D, Roberts AW, et al: Programmed anuclear cell death delimits platelet life span. Cell. 128:1173–1186. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Dolznig H, Habermann B, Stangl K, Deiner EM, Moriggl R, Beug H and Müllner EW: Apoptosis protection by the Epo target Bcl-X(L) allows factor-independent differentiation of primary erythroblasts. Curr Biol. 12:1076–1085. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Garçon L, Rivat C, James C, Lacout C, Camara-Clayette V, Ugo V, Lecluse Y, Bennaceur-Griscelli A and Vainchenker W: Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells. Blood. 108:1551–154. 2006. View Article : Google Scholar | |
|
Harb JG, Chyla BI and Huettner CS: Loss of Bcl-x in Ph+ B-ALL increases cellular proliferation and does not inhibit leukemogenesis. Blood. 111:3760–3769. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Sato T, Hanada M, Bodrug S, Irie S, Iwama N, Boise LH, Thompson CB, Golemis E, Fong L, Wang HG, et al: Interactions among members of the Bcl-2 protein family analyzed with a yeast two-hybrid system. Proc Natl Acad Sci USA. 91:9238–9242. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Minn AJ, Boise LH and Thompson CB: Bcl-x(S) anatagonizes the protective effects of Bcl-x(L). J Biol Chem. 271:6306–6312. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Ohta K, Iwai K, Kasahara Y, Taniguchi N, Krajewski S, Reed JC and Miyawaki T: Immunoblot analysis of cellular expression of Bcl-2 family proteins, Bcl-2, Bax, Bcl-X and Mcl-1, in human peripheral blood and lymphoid tissues. Int Immunol. 7:1817–1825. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Krajewski S, Krajewska M, Shabaik A, Wang HG, Irie S, Fong L and Reed JC: Immunohistochemical analysis of in vivo patterns of Bcl-X expression. Cancer Res. 54:5501–5507. 1994.PubMed/NCBI | |
|
Liles WC and Klebanoff SJ: Regulation of apoptosis in neutrophils-Fas track to death. J Immunol. 155:3289–3291. 1995.PubMed/NCBI | |
|
Sanz C, Benito A, Silva M, Albella B, Richard C, Segovia JC, Insunza A, Bueren JA and Fernández-Luna JL: The expression of Bcl-x is downregulated during differentiation of human hematopoietic progenitor cells along the granulocyte but not the monocyte/macrophage lineage. Blood. 89:3199–3204. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang L, Zhao H, Sun A, Lu S, Liu B, Tang F, Feng Y, Zhao L, Yang R and Han ZC: Early down-regulation of Bcl-xL expression during megakaryocytic differentiation of thrombopoietin-induced CD34+ bone marrow cells in essential thrombocythemia. Haematologica. 89:1199–1206. 2004.PubMed/NCBI | |
|
Gregoli PA and Bondurant MC: The roles of Bcl-X(L) and apopain in the control of erythropoiesis by erythropoietin. Blood. 90:630–640. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Moulding DA, Quayle JA, Hart CA and Edwards SW: Mcl-1 expression in human neutrophils: Regulation by cytokines and correlation with cell survival. Blood. 92:2495–2502. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Park JR, Bernstein ID and Hockenbery DM: Primitive human hematopoietic precursors express Bcl-x but not Bcl-2. Blood. 86:868–876. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Andreeff M, Jiang S, Zhang X, Konopleva M, Estrov Z, Snell VE, Xie Z, Okcu MF, Sanchez-Williams G, Dong J, et al: Expression of Bcl-2-related genes in normal and AML progenitors: Changes induced by chemotherapy and retinoic acid. Leukemia. 13:1881–1892. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Kaufmann SH, Karp JE, Svingen PA, Krajewski S, Burke PJ, Gore SD and Reed JC: Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood. 91:991–1000. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Lotem J and Sachs L: Regulation of bcl-2, bcl-XL and bax in the control of apoptosis by hematopoietic cytokines and dexamethasone. Cell Growth Differ. 6:647–653. 1995.PubMed/NCBI | |
|
Campos L, Sabido O, Viallet A, Vasselon C and Guyotat D: Expression of apoptosis-controlling proteins in acute leukemia cells. Leuk Lymphoma. 33:499–509. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Tsushima H, Urata Y, Miyazaki Y, Fuchigami K, Kuriyama K, Kondo T and Tomonaga M: Human erythropoietin receptor increases GATA-2 and Bcl-xL by a protein kinase C-dependent pathway in human erythropoietin-dependent cell line AS-E2. Cell Growth Differ. 8:1317–1328. 1997.PubMed/NCBI | |
|
Findley HW, Gu L, Yeager AM and Zhou M: Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. Blood. 89:2986–2993. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Bogenberger JM, Kornblau SM, Pierceall WE, Lena R, Chow D, Shi CX, Mantei J, Ahmann G, Gonzales IM, Choudhary A, et al: BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia. 28:1657–1665. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Gottardi D, Alfarano A, De Leo AM, Stacchini A, Aragno M, Rigo A, Veneri D, Zanotti R, Pizzolo G and Caligaris-Cappio F: In leukaemic CD5+ B cells the expression of BCL-2 gene family is shifted toward protection from apoptosis. Br J Haematol. 94:612–618. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Brousset P, Benharroch D, Krajewski S, Laurent G, Meggetto F, Rigal-Huguet F, Gopas J, Prinsloo I, Pris J, Delsol G, et al: Frequent expression of the cell death-inducing gene Bax in Reed-Sternberg cells of Hodgkin's disease. Blood. 87:2470–2475. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Wojtuszkiewicz A, Schuurhuis GJ, Kessler FL, Piersma SR, Knol JC, Pham TV, Jansen G, Musters RJ, van Meerloo J, Assaraf YG, et al: Exosomes secreted by apoptosis-resistant acute myeloid leukemia (AML) blasts harbor regulatory network proteins potentially involved in antagonism of apoptosis. Mol Cell Proteomics. 15:1281–1298. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Datta R, Manome Y, Taneja N, Boise LH, Weichselbaum R, Thompson CB, Slapak CA and Kufe D: Overexpression of Bcl-XL by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation. Cell Growth Differ. 6:363–370. 1995.PubMed/NCBI | |
|
Ibrado AM, Huang Y, Fang G and Bhalla K: Bcl-xL overexpression inhibits taxol-induced Yama protease activity and apoptosis. Cell Growth Differ. 7:1087–1094. 1996.PubMed/NCBI | |
|
Ibrado AM, Huang Y, Fang G, Liu L and Bhalla K: Overexpression of Bcl-2 or Bcl-xL inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells. Cancer Res. 56:4743–4748. 1996.PubMed/NCBI | |
|
Xie C, Edwards H, Caldwell JT, Wang G, Taub JW and Ge Y: Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage. Mol Oncol. 9:409–421. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Huang Y, Ibrado AM, Reed JC, Bullock G, Ray S, Tang C and Bhalla K: Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia. 11:253–257. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Salomons GS, Smets LA, Verwijs-Janssen M, Hart AA, Haarman EG, Kaspers GJ, Wering EV, Der Does-Van Den Berg AV and Kamps WA: Bcl-2 family members in childhood acute lymphoblastic leukemia: Relationships with features at presentation, in vitro and in vivo drug response and long-term clinical outcome. Leukemia. 13:1574–1580. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Dole MG, Clarke MF, Holman P, Benedict M, Lu J, Jasty R, Eipers P, Thompson CB, Rode C, Bloch C, et al: Bcl-xS enhances adenoviral vector-induced apoptosis in neuroblastoma cells. Cancer Res. 56:5734–5740. 1996.PubMed/NCBI | |
|
Sumantran VN, Ealovega MW, Nuñez G, Clarke MF and Wicha MS: Overexpression of Bcl-XS sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res. 55:2507–2510. 1995.PubMed/NCBI | |
|
Deng G, Lane C, Kornblau S, Goodacre A, Snell V, Andreeff M and Deisseroth AB: Ratio of bcl-xshort to bcl-xlong is different in good- and poor-prognosis subsets of acute myeloid leukemia. Mol Med. 4:158–164. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, et al: ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 19:202–208. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, et al: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 435:677–681. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, et al: ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68:3421–3428. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Jilg S, Reidel V, Müller-Thomas C, König J, Schauwecker J, Höckendorf U, Huberle C, Gorka O, Schmidt B, Burgkart R, et al: Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients. Leukemia. 30:112–123. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lessene G, Czabotar PE, Sleebs BE, Zobel K, Lowes KN, Adams JM, Baell JB, Colman PM, Deshayes K, Fairbrother WJ, et al: Structure-guided design of a selective BCL-X(L) inhibitor. Nat Chem Biol. 9:390–397. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Sleebs BE, Kersten WJ, Kulasegaram S, Nikolakopoulos G, Hatzis E, Moss RM, Parisot JP, Yang H, Czabotar PE, Fairlie WD, et al: Discovery of potent and selective benzothiazole hydrazone inhibitors of Bcl-XL. J Med Chem. 56:5514–5540. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, McKeegan E, Salem AH, Zhu M, Ricker JL, et al: Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 6:1106–1117. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Kipps TJ, Anderson MA, Brown JR, Gressick L, et al: Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 374:311–322. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, Puvvada SD, Wendtner CM, Roberts AW, Jurczak W, et al: Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: A multicentre, open-label, phase 2 study. Lancet Oncol. 17:768–778. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lin KH, Winter PS, Xie A, Roth C, Martz CA, Stein EM, Anderson GR, Tingley JP and Wood KC: Targeting MCL-1/BCL-XL forestalls the acquisition of resistance to ABT-199 in acute myeloid leukemia. Sci Rep. 6:276962016. View Article : Google Scholar : PubMed/NCBI | |
|
Punnoose EA, Leverson JD, Peale F, Boghaert ER, Belmont LD, Tan N, Young A, Mitten M, Ingalla E, Darbonne WC, et al: Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models. Mol Cancer Ther. 15:1132–1144. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Schoenwaelder SM, Jarman KE, Gardiner EE, Hua M, Qiao J, White MJ, Josefsson EC, Alwis I, Ono A, Willcox A, et al: Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood. 118:1663–1674. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kile BT: The role of apoptosis in megakaryocytes and platelets. Br J Haematol. 165:217–226. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, Carney DA, He SZ, Huang DC, Xiong H, et al: Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: Results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 30:488–496. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, Liu X, Thummuri D, Yuan Y, Wiegand JS, et al: A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 25:1938–1947. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
He Y, Zhang X, Chang J, Kim HN, Zhang P, Wang Y, Khan S, Liu X, Zhang X, Lv D, et al: Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity. Nat Commun. 11:19962020. View Article : Google Scholar : PubMed/NCBI | |
|
Tao ZF, Hasvold L, Wang L, Wang X, Petros AM, Park CH, Boghaert ER, Catron ND, Chen J, Colman PM, Czabotar PE, et al: Discovery of a potent and selective BCL-XL inhibitor with in vivo activity. ACS Med Chem Lett. 5:1088–1093. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Q, Wan J, Zhang W and Hao S: MCL-1 or BCL-xL-dependent resistance to the BCL-2 antagonist (ABT-199) can be overcome by specific inhibitor as single agents and in combination with ABT-199 in acute myeloid leukemia cells. Leuk Lymphoma. 60:2170–2180. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu Y, Doornebal EJ, Pirtskhalava T, Giorgadze N, Wentworth M, Fuhrmann-Stroissnigg H, Niedernhofer LJ, Robbins PD, Tchkonia T and Kirkland JL: New agents that target senescent cells: The flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463. Aging (Albany NY). 9:955–963. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Doherty GA, Judd AS, Tao ZF, Hansen TM, Frey RR, Song X, Bruncko M, Kunzer AR, Wang X, et al: Discovery of A-1331852, a First-in-Class, potent, and orally-bioavailable BCL-XL inhibitor. ACS Med Chem Lett. 11:1829–1836. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kirkland JL and Tchkonia T: Cellular senescence: A translational perspective. EBioMedicine. 21:21–28. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Perri M, Yap JL, Yu J, Cione E, Fletcher S and Kane MA: BCL-xL/MCL-1 inhibition and RARγ antagonism work cooperatively in human HL60 leukemia cells. Exp Cell Res. 327:183–191. 2014. View Article : Google Scholar : PubMed/NCBI |
